Holen Sie sich die Stockscreener-App
42.23
5.29%
2.12
Moderna Inc Aktie (MRNA) Neueste Nachrichten
CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot - The Cancer Letter
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
Moderna CEO Worries About Drug Development Overall After US FDA mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna looks outside US for growth after FDA’s flu shot refusal - whbl.com
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results - FinancialContent
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend - FXEmpire
Moderna Reports a Narrower-Than-Expected Loss. The Stock Slips After Earnings. - Barron's
Moderna Has A Few Words For The FDA After mRNA-1010 Refusal-To-File - Citeline News & Insights
Moderna, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Moderna: Q4 Earnings Snapshot - theheraldreview.com
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial Challenges - GuruFocus
Moderna (MRNA) Faces Challenges Amid Renewed Interest in Biotech Sector - GuruFocus
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop - GuruFocus
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Moderna's mRNA Technology Has Potential Across Vaccines, Oncology, and Rare Diseases - Morningstar
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results, Beats Estimates By $0.68 EPS - MarketBeat
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates - The Desert Sun
Moderna Reports 4Q Revenue Of $678 Million, Projects 2026 Growth - AlphaStreet News
Moderna shares jump as company affirms growth outlook - BioPharma Dive
Moderna shares pop on strong guidance, smaller-than-expected loss - Yahoo Finance
Pink Sheet Podcast: US FDA Versus Moderna And The Changing Role Of Refuse To File Actions - Citeline News & Insights
Moderna climbs 11% after Q4 revenue beats estimates - breakingthenews.net
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates - TradingView
FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’ - The Guardian
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation - BioSpace
Moderna beats Q4 revenue estimate - BNN Bloomberg
Moderna (MRNA) Shares Rise Despite FDA Rejection of Flu Vaccine Application - GuruFocus
Moderna tops Q4 2025 EPS by 51c, beats on revenue - The Pharma Letter
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms - Benzinga
Moderna (NASDAQ:MRNA) Trading 7.2% Higher Following Better-Than-Expected Earnings - MarketBeat
Moderna Maintains Full-Year Revenue Growth Outlook Following Fourth-Quarter Beat - marketscreener.com
Moderna Q4 Earnings Call Highlights - MarketBeat
Moderna Shares Rise After Q4 Loss Narrows, Revenue Beats Estimates - marketscreener.com
Softer-Than-Expected Inflation Sparks Rally In These 10 Stocks - Benzinga
Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, and More Movers - Barron's
Moderna Q4 2025 slides reveal strategic pivot as losses narrow, shares climb - Investing.com
Moderna Sales Beat as Covid Shot Demand Falls Less Than Expected - Bloomberg.com
Earnings call transcript: Moderna’s Q4 2025 results exceed expectations - Investing.com
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls - The Wall Street Journal
Moderna Reiterates 10% Revenue-Growth Target as Covid Vaccine Demand Falls -- Update - marketscreener.com
Moderna Q4 Loss Narrows - Nasdaq
AI for investors - MLQ.ai
Moderna beats quarterly revenue estimates on resilient COVID shot sales - BNN Bloomberg
A Political Appointee Overruled FDA Scientists to Block Moderna's Flu Vaccine — and the Fallout Is Just Beginning - WebProNews
Applied Materials, Arista, Moderna, Coinbase, DraftKings, Steel Dynamics, Rivian, Roku, and More Movers - Barron's
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way - 24/7 Wall St.
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna (MRNA) Surpasses Q4 Earnings Expectations Despite Revenue Decline - GuruFocus
Moderna (MRNA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Moderna Narrows Loss, Reiterates 10% Revenue Growth Target - The Wall Street Journal
Moderna beats quarterly revenue estimates on resilient sales of COVID shot - marketscreener.com
Moderna announces influenza vaccine filing accepted for regulatory review in the EU - marketscreener.com
Moderna (MRNA) Exceeds Revenue Estimates and Looks Ahead to Growth - GuruFocus
Moderna beats fourth-quarter revenue estimates - marketscreener.com
Moderna reports a narrower-than-expected loss. The stock slips after earnings - MSN
Why did the U.S. FDA decline to review the new mRNA influenza vaccine? - The Hindu
Moderna reaffirms 2026 growth after Q4 beat (MRNA:NASDAQ) - Seeking Alpha
Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations - The Globe and Mail
Moderna's Q4 Net Loss Narrows, Revenue Declines; Reiterates 2026 Revenue Growth Outlook - marketscreener.com
Moderna's Q4 revenue falls 30% to $678 million - breakingthenews.net
Earnings Flash (MRNA) Moderna, Inc. Reports Q4 Revenue $678.0M, vs. FactSet Est of $635.2M - marketscreener.com
Moderna reports Q4 earnings beat, upbeat 2026 outlook - Sherwood News
Moderna beats Q4 expectations, but stock edges lower on FDA setback - Investing.com
Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings. - Barron's
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):